Plus Therapeutics, Inc. (PSTV) Stock Price & Analysis
Plus Therapeutics, Inc. (PSTV) fell 0.54% to USD 5.5 as of June 10, 2026 at 03:27 UTC, according to Nexqual real-time market data.
PSTV last closed at USD 5.53; the session ranged USD 5.11–5.72 on volume of 106,524 shares. Market capitalization is $37.86M, with a 52-week range of USD 2.9–23.5 (NCM). Source: Nexqual, June 10, 2026 at 03:27 UTC.
Key Statistics (as of June 10, 2026 at 03:27 UTC)
| Price | USD 5.5 |
|---|---|
| Change | ▼ 0.54% (down) |
| Previous Close | USD 5.53 |
| Open | USD 5.41 |
| Day Range | USD 5.11 – 5.72 |
| 52-Week Range | USD 2.9 – 23.5 |
| Volume | 106,524 shares |
| Market Cap | $37.86M |
| Exchange | NCM |
Technical Analysis (PSTV)
Nexqual's technical model rates PSTV "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.8 (neutral) |
| vs SMA50 | Below (USD 5.69) |
| MACD | -0.14 (negative) |
Analyst Ratings (PSTV)
Wall Street analysts rate PSTV "Strong Buy" based on 4 analysts, with a mean price target of USD 36 (range USD 12–57), per Nexqual as of June 10, 2026 at 03:27 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 36 |
| High Target | USD 57 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (PSTV)
| EPS Estimate | USD -0.88 |
|---|---|
| Revenue Estimate | $1.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.05 vs est -0.87 ▼ miss |
| 2025-12-31 | USD 0 vs est -0.92 ▲ beat |
| 2025-09-30 | USD -1 vs est -0.88 ▼ miss |
| 2025-06-30 | USD -0.16 vs est -3.25 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
Financials & Fundamentals (PSTV)
| Total Revenue | $5.18M |
|---|---|
| Revenue Growth (YoY) | -2.90% |
| Gross Margin | -83.09% |
| Operating Margin | -692.51% |
| Profit Margin | -230.24% |
| Debt / Equity | 6.06 |
| Current Ratio | 2.27 |
| Total Cash | $15.11M |
| Total Debt | $725,000 |
| Free Cash Flow | $-15.11M |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
Financial Health Score (PSTV)
Nexqual rates Plus Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:27 UTC.
| Growth | Critical — Revenue -10% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $15M cash, no debt |
| Cash Flow | Weak — FCF negative: -$15M, burning cash |
| Efficiency | Mixed — No data |
Ownership (PSTV)
| Insider Ownership | +1.49% |
|---|---|
| Institutional Ownership | +10.38% |
| Shares Outstanding | 6.88M |
| Float | 6.48M |
| Short % of Float | +16.69% |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
Leadership (PSTV)
Plus Therapeutics, Inc. is led by Marc H. Hedrick (age 62), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:27 UTC.
| President, CEO & Director | Marc H. Hedrick (age 62) |
|---|---|
| VP & CFO | Andrew J. Sims (age 52) |
| Executive Vice President of Commercial and Corporate Strategy | Russ Havranek M.B.A., M.S. |
| President & GM of CNSide Diagnostics, LLC | Russell W. Bradley (age 61) |
Major Backers & Investors (PSTV)
Notable institutional backers of Plus Therapeutics, Inc. include Fidelity, Millennium Management, according to Nexqual as of June 10, 2026 at 03:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.96% |
| Millennium Management | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.5% |
| Geode Capital | 1.17% |
| BlackRock | 1.03% |
| State Street | 0.27% |
| Northern Trust | 0.17% |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
From Plus Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
- The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
- It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection.
- In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
| ADTX | Aditxt, Inc. | USD 0.03 | ▼ 53.39% |
| RKTO | Rocket One Inc. | USD 1.28 | ▼ 15.23% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:27 UTC. This page is informational and not investment advice.